WORCESTER, MA--(MARKET WIRE)--Jun 12, 2007 -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Rodman & Renshaw, a New York-based investment bank, initiated coverage of the Company with a “Market Outperform” rating and an 18-month price target of $6.00. The report was issued by Navdeep S. Jaikaria, Ph.D., a Managing Director in the Equity Research Division.
